Kyverna Therapeutics (KYTX) Interest Expenses (2023 - 2026)
Kyverna Therapeutics posted quarterly Interest Expenses of $667000.0 for Q1 2026, up 2568.0% year-on-year from $25000.0 in Q1 2025, and up 50.23% on a QoQ basis from $444000.0 in Q4 2025.
Kyverna Therapeutics (KYTX) has 4 years of Interest Expenses data on file, last reported at $667000.0 in Q1 2026.
- For the quarter ending Q1 2026, Interest Expenses rose 2568.0% year-over-year to $667000.0; the trailing twelve-month figure through Mar 2026 stood at $1.1 million (up 820.33% YoY), and the FY2025 full-year result was $489000.0, up 244.37% from the prior year.
- Interest Expenses for Q1 2026 stood at $667000.0, up from $444000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $667000.0 in Q1 2026 and bottomed at $7000.0 in Q3 2025.
- The 4-year median for Interest Expenses is $44000.0 (2023), against an average of $114307.7.
- The widest annual swing landed in 2025, when Interest Expenses tumbled 78.12%; it then jumped 2568.0% in 2026.
- A 4-year view of Interest Expenses shows it stood at $47000.0 in 2023, then plunged by 42.55% to $27000.0 in 2024, then surged by 1544.44% to $444000.0 in 2025, then soared by 50.23% to $667000.0 in 2026.
- The last three Interest Expenses figures came in at $667000.0 (Q1 2026), $444000.0 (Q4 2025), and $7000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 22,854.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -5.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 61,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -332,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 12.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 69.29 Mn |
| 10 | Kyverna Therapeutics | 497.98 Mn | 265.03 Mn | - | 667,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 667,000.00 |
| Mar 31, 2026 | 667,000.00 |
| Dec 31, 2025 | 444,000.00 |
| Dec 31, 2025 | 444,000.00 |
| Sep 30, 2025 | 7,000.00 |
| Sep 30, 2025 | 7,000.00 |
| Jun 30, 2025 | 14,000.00 |
| Jun 30, 2025 | 14,000.00 |
| Mar 31, 2025 | 25,000.00 |
| Mar 31, 2025 | 25,000.00 |
| Dec 31, 2024 | 27,000.00 |
| Dec 31, 2024 | 27,000.00 |
| Sep 30, 2024 | 32,000.00 |
| Sep 30, 2024 | 32,000.00 |
| Jun 30, 2024 | 39,000.00 |
| Jun 30, 2024 | 39,000.00 |
| Mar 31, 2024 | 44,000.00 |
| Mar 31, 2024 | 44,000.00 |
| Dec 31, 2023 | 47,000.00 |
| Dec 31, 2023 | 47,000.00 |
| Sep 30, 2023 | 50,000.00 |
| Sep 30, 2023 | 50,000.00 |
| Jun 30, 2023 | 46,000.00 |
| Jun 30, 2023 | 46,000.00 |
| Mar 31, 2023 | 44,000.00 |
| Mar 31, 2023 | 44,000.00 |